Thus, the aim of this manuscript is to investigate whether manipulation of the TGF-β signaling pathway, using a specific inhibitor, is able to enhance sensitivity to chemotherapeutic drugs in different GC cell lines. Here, TGFB1 is linked to gastric cancer.